scholarly journals Re: The first report on coronavirus disease 2019 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey

2021 ◽  
Author(s):  
Luigi Cavanna ◽  
Chiara Citterio ◽  
Evelina Cattadori ◽  
Costanza Bosi ◽  
Serena Caprioli
Keyword(s):  
Early Data ◽  
First Report ◽  
Patients With Cancer ◽  
Vaccine Refusal

scholarly journals Letter to Editor, Re: The first report on Covid-19 vaccine refusal by cancer patients in Italy: early data from a single-institute survey

2021 ◽  
Author(s):  
Cynthia Villarreal-Garza ◽  
Bryan F. Vaca-Cartagena ◽  
Andrea Becerril-Gaitan ◽  
Fernando Castilleja-Leal
Keyword(s):  
Cancer Patients ◽  
Early Data ◽  
First Report ◽  
Vaccine Refusal

scholarly journals The first report on Covid-19 vaccine refusal by cancer patients in Italy: early data from a single-institute survey

2021 ◽  
Author(s):  
Vincenzo Di Noia ◽  
Davide Renna ◽  
Vittoria Barberi ◽  
Mattia Dicivita ◽  
Federica Riva ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Early Data ◽  
First Report ◽  
Vaccine Refusal

scholarly journals First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome

Reumatismo ◽  
2017 ◽  
Vol 69 (2) ◽  
pp. 75 ◽  
Author(s):  
B. Palterer ◽  
G. Vitiello ◽  
D. Cammelli
Keyword(s):  
Young Adults ◽  
Elderly Patients ◽  
Myelodysplastic Syndrome ◽  
Juvenile Dermatomyositis ◽  
Inflammatory Myopathies ◽  
First Report ◽  
Patients With Cancer ◽  
First Case

Inflammatory myopathies as para-neoplastic phenomena were first described by Sterz in 1916. Recently, myositis specific autoantibodies were described in cancer-associated myositis. Anti-transcription intermediary factor 1 gamma (anti-TIF1γ) antibodies have been found in both young adults affected by juvenile dermatomyositis and in elderly patients with cancer-associated myositis. In this regard, we report herein the first case of anti-TIF1γ dermatomyositis secondary to a myelodysplastic syndrome.

A fossil Aspergillus from Eocene Dominican amber

1988 ◽  
Vol 62 (01) ◽  
pp. 141-143 ◽  
Author(s):  
Gerard M. Thomas ◽  
George O. Poinar
Keyword(s):  
Dominican Republic ◽  
Fossil Species ◽  
First Report ◽  
Dominican Amber ◽  
Eocene Amber

A sporulating Aspergillus is described from a piece of Eocene amber originating from the Dominican Republic. The Aspergillus most closely resembles a form of the white spored phase of Aspergillus janus Raper and Thom. This is the first report of a fossil species of Aspergillus.

1392: First Report of a New Transurethral Detaching Prostatectomy of the Prostate (TUDP)

2005 ◽  
Vol 173 (4S) ◽  
pp. 377-378
Author(s):  
Yasunori Hiraoka ◽  
Kazuhiko Yamada ◽  
Yuji Shimizu ◽  
Hiroyuki Abe
Keyword(s):  
First Report

L-arginine effect on inflammatory mediators: A systematic review of randomized controlled clinical trials

2019 ◽  
pp. 1-9 ◽  
Author(s):  
Seyed Reza Mirhafez ◽  
Mitra Hariri
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Inflammatory Mediators ◽  
Randomized Clinical Trials ◽  
Randomized Controlled Clinical Trials ◽  
Patients With Cancer ◽  
Reactive Protein ◽  
Randomized Controlled ◽  
Human Adults ◽  
Factor Α

Abstract. L-arginine is an important factor in several physiological and biochemical processes. Recently, scientists studied L-arginine effect on inflammatory mediators such as C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). We conducted a systematic review on randomized controlled trials assessing L-arginine effect on inflammatory mediators. We searched data bases including Google scholar, ISI web of science, SCOPUS, and PubMed/Medline up to April 2019. Randomized clinical trials assessing the effect of L-arginine on inflammatory mediators in human adults were included. Our search retrieved eleven articles with 387 participants. Five articles were on patients with cancer and 6 articles were on adults without cancer. L-arginine was applied in enteral form in 5 articles and in oral form in 6 articles. Eight articles were on both genders, two articles were on women, and one article was on men. L-arginine could not reduce inflammatory mediators among patients with and without cancer except one article which indicated that taking L-arginine for 6 months decreased IL-6 among cardiopathic nondiabetic patients. Our results indicated that L-arginine might not be able to reduce selected inflammatory mediators, but for making a firm decision more studies are needed to be conducted with longer intervention duration, separately on male and female and with different doses of L-arginine.

Sign in / Sign up

Export Citation Format

Share Document